Hims & Hers Stock Declines Amid Revenue Miss and Growth Concerns
Hims & Hers stock dropped over 11% after missing Wall Street's Q2 sales forecast despite higher profits, as the company shifts focus to personalized healthcare and faces challenges in its obesity-related business. The company maintains its annual sales guidance but faces scrutiny over its core business and recent market performance, amid a broader industry context involving weight-loss drugs and strategic partnerships.